the BRCA1 and BRCA2 Cohort Consortium IMPORTANCE The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates.
T he optimal clinical management of women with BRCA1 and BRCA2 mutations depends on accurate agespecific cancer risk estimates. These can be used to estimate the absolute risk reduction from preventive strategies and to inform decisions about the age at which to commence cancer screening. 1 Based on retrospective studies, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] cumulative breast cancer risk estimates to age 70 years range from 40% to 87% for BRCA1 and from 27% to 84% for BRCA2 carriers. The corresponding ovarian cancer risks vary from 16% to 68% for BRCA1 and from 11% to 30% for BRCA2 carriers. Risk estimates from these studies had wide confidence intervals. Differences in sampling (population-based/high-risk families), population and mutation characteristics, analytic methods, and other genetic and lifestyle/hormonal factors are possible explanations for the variation in risk estimates. 12 Because BRCA1 and BRCA2 mutations are rare in the population, most retrospective penetrance estimates have been derived from family-based studies. Typically, mutation screening has been performed among affected women, selected on the basis of young age at diagnosis or cancer family history. Cancer risks are then estimated using the known or inferred genotypes of the relatives. Estimates from such retrospective, family-based studies are prone to bias if analyses are not correctly adjusted for the ascertainment process or if there are inaccuracies in family history.
Prospective cohort studies, in which mutation carriers are recruited on the basis of their mutation status and followed over time, may avoid these issues. Because the precision of risk estimates depends on the number of prospective incident cancers, a very large sample with long follow-up is required. Prospective penetrance estimates have been based on small samples (<64 breast cancers, 31 ovarian cancers) and are imprecise. [13] [14] [15] The purpose of this study was to estimate agespecific risks of breast, ovarian, and contralateral breast cancer using data from a large prospective cohort.
Methods

Participants
We used prospective cohort data on carriers of pathogenic BRCA1 and BRCA2 mutations recruited through 3 consortia, the International BRCA1/2 Carrier Cohort Study (IBCCS), the Breast Cancer Family Registry (BCFR), and the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer (kConFab) (eAppendix in the Supplement). All centers in these consortia obtained written informed consent from study participants and local ethical review committees approved protocols. Briefly, for the IBCCS, data were available from 7666 female carriers recruited between 1997 and 2011 from 18 European cancer genetics centers and the Quebec province of Canada. The majority were from large national studies in the United Kingdom, the Netherlands, and France. All centers conducted active follow-up through questionnaires. In addition to the active follow-up in all studies, passive follow-up through linkage with cancer, pathology, and death registries was obtained in countries where this is available (cancer/death registries in Denmark, the Netherlands, Sweden, and the United Kingdom; pathology registries to collect information on preventive surgeries in Denmark and the Netherlands), together with medical record validation of selfreported cancer diagnoses and preventive surgeries.
The BCFR is a family cohort that includes data on 1570 mutation carriers recruited from 6 sites in Australia, Canada, and the United States. Families were followed up regularly through annual approaches to probands and 5-year systematic follow-up of families collecting epidemiological and demographic data from all participants.
The kConFab study included 620 mutation carriers from multiple-case families ascertained through family cancer clinics in Australia and New Zealand since 1997. Participants were systematically followed up using a questionnaire mailed every 3 years.
The end of follow-up was December 2013.
Eligibility and Censoring
For each of the 3 analyses (breast cancer risk, contralateral breast cancer risk, and ovarian cancer risk), we defined a different group eligible at baseline ( Figure 1 ). Age at baseline was defined as age at study recruitment or age at the genetic test, whichever was more recent.
Breast Cancer Risk
Women were included in the estimation of first breast cancer risk if at completion of the baseline questionnaire they had not been diagnosed as having any cancer (excluding nonmelanoma skin cancer) nor undergone risk-reducing bilateral mastectomy (with mastectomy: n = 304 BRCA1; n=1 4 8BRCA2) (eAppendix in the Supplement). Women were followed up from baseline until the first of the following: age 80 years; death; completion of last follow-up questionnaire or last record linkage (if conducted), whichever happened last; risk-reducing bilateral mastectomy; or diagnosis of any first cancer (excluding nonmelanoma skin cancer). Women diagnosed as having breast cancer (invasive or noninvasive [ductal carcinoma in situ]) during follow-up were considered as affected. Because information on cancers was partly self reported, tumor phenotype-specific data were not available other than for invasiveness. Therefore, all types of breast cancer were included in the analysis. Additional analyses were performed in which (1) affected women were considered to be only those diagnosed as having invasive disease and (2) women were censored at the age of risk-reducing salpingo-oophorectomy (eAppendix).
Ovarian Cancer Risk
Women were included in the ovarian cancer analysis if at baseline they had not been diagnosed as having ovarian cancer nor undergone risk-reducing salpingo-oophorectomy (with oophorectomy: n = 1808 BRCA1;n=9 6 9BRCA2).
Women with a history of breast or nonmelanoma skin cancer were included in the analysis but women with other cancers were not. Women were followed up from baseline until the first of the following: age 80 years; death; completion of last follow-up questionnaire or last record linkage (whichever happened last); risk-reducing salpingo-oophorectomy (or salpingectomy or removal of ovaries for other reasons); or any cancer diagnosis (excluding breast and nonmelanoma skin cancer). Only women diagnosed as having invasive ovarian (or fallopian tube or peritoneal) cancer during follow-up were considered affected.
Contralateral Breast Cancer Risk
Women were included in the contralateral breast cancer analysis if they were diagnosed as having a first breast cancer before the date of their last follow-up questionnaire (or record linkage) and had not been diagnosed as having any other cancer (including contralateral breast cancer) nor undergone risk-reducing bilateral mastectomy before study entry. Only asynchronous contralateral breast cancer was considered, for which there had to be an interval of at least 1 year between first and second breast cancers. Eligible women entered follow-up at their baseline questionnaire date or 1 year after their first breast cancer diagnosis date (whichever was later) and were followed up until the first of the following: age 80 years; death; date at last follow-up; risk-reducing bilateral mastectomy; or any cancer. Women diagnosed as having asynchronous contralateral breast cancer during follow-up were assumed to be affected.
Statistical Analysis
Annual incidences of breast, ovarian, and contralateral breast cancer per 1000 person-years were estimated for 10-year age intervals using standard cohort analysis. Kaplan-Meier analysis was used to estimate cumulative risks. Standardized incidence ratios (SIRs) for breast and ovarian cancer relative to population-specific incidences were also estimated (eAppendix in the Supplement). We used Cox-regression to compare cancer risks for BRCA1 mutation carriers with risks for BRCA2 carriers across all age groups and by attained age. To test for heterogeneity by country, we carried out Cox regression estimating hazard ratios (HRs) for each country (n=6) compared with the baseline (United Kingdom); a χ 2 (n − 1) degree-offreedom test was carried out on the estimated HRs to test for heterogeneity. The contralateral breast cancer analysis was stratified by age at first breast cancer (<40 years, 40-49 years, or ≥50 years) and Cox regression was used to compare risks between age groups. We evaluated cancer risks by extent of self-reported family history of breast or ovarian cancer separately (eAppendix in the Supplement). Women were classified by the number of cancers in first-or seconddegree relatives (0, 1, or ≥2). Separate categories for women with cancers of unknown type among relatives and for those with unknown family history (missing data) were defined, and separate HRs were estimated for these categories. A test for trend was performed using Cox regression by including a continuous variable in the model representing the number of breast or ovarian cancers in female first-or second-degree relatives (taking values of 0, 1, 2, 3, etc). (before 1940, 1940-1949, 1950-1959, 1960-1969, 1970-1979, or 1980 or later) . Proportionality was evaluated using Schoenfeld residuals, which was met for all analyses. Analyses were carried out in Stata version 13 (Stata Corp). Statistical tests were considered significant based on 2-sided hypothesis tests with P < .05.
Results
A total of 9856 participants including 6036 BRCA1 and 3820 BRCA2 mutation carriers were available at baseline. The majority of women were ascertained through family clinics (94%), and the remainder (6%) were recruited from studies that used population-based ascertainment. Figure 1 and eTable 1 in the Supplement summarize the baseline cohort study sample (N = 9856) and the assembly of the eligible prospective cohorts for each analysis. Table 1 summarizes the characteristics of the eligible women included in the prospective analyses. Information on follow-up completeness is summarized in eTable 2 in the Supplement. All studies conducted active follow-up with questionnaires, but the mean interval between questionnaires varied across studies (1.6 to 8.7 years) (eTable 2). In addition, in countries with registry information, active follow-up was complemented with passive follow-up through record linkage. On average, 7% of women in the cohort were lost to follow-up, but this varied among studies (0% to 13%) (eTable 2). The breast cancer analysis was based on 3886 eligible BRCA1 and BRCA2 mutation carriers (median age at study entry, 38 years; interquartile range [IQR] , 30-46 years). The ovarian cancer analysis was based on data from 5066 women (median age at study entry, 38 years; IQR, 31-47 years) and the contralateral breast cancer analysis was based on 2213 women (median age at start of follow-up, 47 years; IQR, 40-55 years). During follow-up, among the eligible women, 426 were diagnosed as having breast cancer (483 censored for risk-reducing bilateral mastectomy), 109 were diagnosed as having ovarian cancer (1508 censored for risk-reducing salpingo-oophorectomy), and 245 were diagnosed as having asynchronous contralateral breast cancer. The age-specific cancer incidences, SIRs, and cumulative risks are shown in Table 2 .
Breast Cancer Risks
For BRCA1 carriers, the breast cancer incidences per decade of age increased from 21 to 30 years to 31 to 40 years but then remained at 23.5 to 28.3 per 1000 person-years for ages 31 to 70 years (P = .97 for trend). The peak incidence occurred in the 41-to 50-year age group (28.3 [95% CI, per 1000 person-years). A similar pattern was seen for BRCA2 carriers, with peak incidence in the 51-to 60-year age group (30.6 [95% CI, .1] per 1000 person-years) and incidences of 21.9 to 30.6 per 1000 person-years across ages 41 to 80 years (P =.57for trend). The estimated SIRs decreased with increasing age in both BRCA1 carriers (P<.001 for trend) and BRCA2 carriers (P<.001 for trend). The cumulative risk of breast cancer by age 80 years was 72% (95% CI, 65%-79%) for BRCA1 carriers and 69% (95% CI, 61%-77%) for BRCA2 carriers ( Figure 2 ). While the cumulative risks for BRCA1 and BRCA2 carriers to age 80 years were similar, the cumulative risks to age 50 years were higher for BRCA1 carriers (P = .03).
The cumulative risk estimates for breast cancer by age 80 years when censoring at risk-reducing salpingo-oophorectomy were 70% (95% CI, 60%-80%) for BRCA1 carriers and 75% (95% CI, 67%-83%) for BRCA2 carriers (eTable 3 and eFigure 1 in the Supplement). From an analysis that excluded known in situ breast cancers, the corresponding risk estimates were 68% (95% CI, 60%-76%) for BRCA1 carriers and 63% (95% CI, 54%-72%) for BRCA2 carriers (eTable 4 in the Supplement).
There were no significant differences in the estimated breast cancer incidences by country for either BRCA1 carriers (P = .32 for heterogeneity) or BRCA2 carriers (P = .43 for heterogeneity) (eTable 5 and eFigure 2 in the Supplement). The estimated breast cancer risks were similar when analyses were carried out separately for women identified through family clinics and women who were relatives of mutation carriers identified through populationwide screening of breast cancer cases (eTable 6 in the Supplement).
Ovarian Cancer Risks
There was an increase in ovarian cancer incidence with age up to 61 to 70 years for both BRCA1 and BRCA2 carriers. The incidences were higher for BRCA1 carriers (HR comparing BRCA1 vs BRCA2, 3.6; 95% CI, 2.2-5.9; P < .001). The SIRs did not vary with age for either gene (BRCA1: overall SIR, 49.6 [95% CI, 40.0-61.5]; P = .86 for trend; BRCA2: 13. 7 [95% CI, ; P =.23 for trend). The ovarian cancer cumulative risk to age 80 years was 44% (95% CI, 36%-53%) for BRCA1 carriers and 17% (95% CI, 11%-25%) for BRCA2 carriers (Table 2 and Figure 2 ).
Contralateral Breast Cancer Risks
The estimated incidence of contralateral breast cancer for BRCA1 carriers varied between 23 and 28 per 1000 personyears for the period up to 20 years after the first breast cancer diagnosis ( For BRCA2 carriers, the estimated contralateral breast cancer incidence varied between 13 and 18 per 1000 personyears during the years after the first breast cancer diagnosis. The cumulative risk of contralateral breast cancer at 20 years after the first breast cancer diagnosis was 26% (95% CI, 20%-33%) and was lower than for BRCA1 carriers (HR comparing BRCA2 vs BRCA1 carriers, 0.62; 95% CI, 0.47-0.82; P = .001). The HR for contralateral breast cancer when first breast cancer diagnosis was between ages 40 and 50 years was 0.73 (95% CI, 0.41-1.26), and when the first breast cancer diagnosis was at age greater than 50 years, the HR was 0.76 (95% CI, 0.43-1.36) compared with a first breast cancer before age 40 years. When women were censored at the age of risk-reducing salpingo-oophorectomy, the contralateral breast cancer risks at 20 years after the first breast cancer were 38% (95% CI, 31%-45%) for BRCA1 carriers and 34% (95% CI, 25%-45%) for BRCA2 carriers (eTable 8 in the Supplement).
To investigate potential survival bias, the analysis was repeated after excluding women whose first breast cancer diagnosis occurred more than 5 years prior to study recruitment. The estimated cumulative risk of contralateral breast cancer at 20 years after the first breast cancer diagnosis was 41% (95% CI, 32%-53%) for BRCA1 and 21% (95% CI, 15%-50%) for BRCA2 carriers.
Breast and Ovarian Cancer Risks by Family History
The estimated cumulative breast and ovarian cancer risks by family history are shown in Table 4 and eFigure 3 in the Supplement. Breast cancer risk estimates for both BRCA1 and BRCA2 carriers increased with the number of first-and seconddegree relatives diagnosed as having breast cancer (P<.001 for trend for BRCA1; P=.02 for BRCA2) ( (Table 4 ). There was no significant difference in ovarian cancer risk for BRCA1 carriers with family history of ovarian cancer compared with those without (HR, 1.37; 95% CI, 0.89-2.11) ( Table 4 ; eFigure 3 in the Supplement). A similar pattern was observed for BRCA2 carriers, but the number of events for women with ovarian cancer family history was small (n = 5). Results were similar when family history of cancer was restricted to first-degree relatives (eTable 9 in the Supplement) or when analyses were stratified by the presence of family history of breast or ovarian cancer (eTables 10-13 in the Supplement). For BRCA1 mutation carriers, the risk of breast cancer was lower for women with a family history of ovarian cancer compared with those with no family history of ovarian cancer (HR, 0.71 [95% CI, 
Breast and Ovarian Cancer Risks by Mutation Position
BRCA1 mutations located outside the region bounded by positions c.2282 to c.4071 were associated with a significantly higher breast cancer risk compared with mutations within the region (HR, 1.46; 95% CI, 1.11-1.93; P = .007) ( Table 5 ; eFigure 4 in the Supplement), but there was no significant difference in ovarian cancer risk. There was no significant difference in the breast or ovarian cancer risks for either the BRCA1 c.68_69delAG or c.5266dupC mutations compared with BRCA1 mutations in the same region (Table 5 ). BRCA2 mutations outside the OCCR were associated with a significantly higher breast cancer risk compared with mutations within the OCCR (based on the narrow OCCR definition: HR, 1.70 [95% CI, 1.18-2.46]; P = .005; based on the broad OCCR definition: HR, 1.93 [95% CI, 1.36-2.74]; P < .001) ( Table 5 ), but there was no significant difference in ovarian cancer risk. There was no significant difference in breast cancer risk for BRCA2 c.5946delT mutation carriers compared with other OCCR BRCA2 mutations (HR, 0.73; 95% CI, 0.35-1.54; P = .41). The associations by mutation position remained significant after adjusting for family history of breast cancer and after excluding carriers of the BRCA2 c.5946delT mutation from the OCCR (eTable 14 in the Supplement).
Discussion
This study estimated age-specific risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation Cumulative risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers
B
Kaplan-Meier estimates of cumulative risks of breast and ovarian cancers.
In the breast cancer analysis, women were censored at risk-reducing bilateral mastectomy. In the ovarian cancer analysis, women were censored for risk-reducing salpingo-oophorectomy. Number at risk indicates the number of women who remained at risk at the end of the 10-year age category (eg, in panel A, there were 138 women with BRCA1 mutations still at risk of breast cancer at the end of the age 50-60 years period). The earliest follow-up started at age 18 years.
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Risks of Breast, Ovarian, and Contralateral Breast Cancer Among BRCA Mutation Carriers carriers using data from a prospective cohort. Because the study mainly included unaffected women identified by mutation screening based on cancer family history, early age at onset of a family member, or both, the overall estimates are relevant to mutation carriers identified through clinical testing. However, the wide range of family histories represented allowed an examination of the relationship between family history and cancer risk. The results indicate that family history is a strong risk factor for mutation carriers and that cancer risks vary by mutation location, suggesting that individualized counseling should incorporate both family history profiles and mutation location.
The cumulative risk of developing breast cancer by age 80 years was 72% for BRCA1 mutation carriers and 69% for BRCA2 mutation carriers, respectively. For ovarian cancer, the cumulative risks by age 80 years were 44% for BRCA1 carriers and 17% for BRCA2 carriers. Breast cancer incidence for carriers increased rapidly with age in early adulthood then plateaued to remain relatively constant throughout the remaining lifetime. The age at which this plateau was reached was 31 to 40 years for BRCA1 carriers and 5 to 10 years later for BRCA2 carriers. The incidence during the plateau was similar for both groups of mutation carriers. This is consistent with the model for genetic risk of breast cancer based on twin data, 20 in which the age-specific incidence for genetically susceptible women increases to a high constant level by a predetermined age that varies among families. The estimated breast and ovarian cancer risks were consistent with findings from retrospective family-based studies. 2, 3, 6, 10 The breast cancer SIRs decreased with increasing age for both BRCA1 and BRCA2 carriers, but the estimates were higher than those previously reported for younger age groups. 2, 21 From this prospective study, the estimated cumulative risks of ovarian cancer were low up to age 40 years for BRCA1 mutation carriers and up to age 50 years for BRCA2 mutation carriers. This study was limited in the extent to which differences by birth cohort could be assessed because birth cohort was strongly associated with age. For age intervals with sufficient observations, there was no evidence of risk differences by birth cohort (eFigure 5 in the Supplement).
In line with retrospective studies of contralateral breast cancer risks, 22,23 the present prospective analysis of BRCA1 and BRCA2 carriers combined demonstrated a higher risk when the first breast cancer was diagnosed before age 40 years vs after age 50 years (P = .03).
The contralateral breast cancer analysis also included women diagnosed as having breast cancer prior to study recruitment. The median interval between first breast cancer diagnosis and study recruitment was 4 years, and this did not vary by age at first breast cancer diagnosis or by gene. The inclusion of survivors could potentially bias the estimation of contralateral breast cancer risks if such risks were related to the outcome of the first cancer; however, there is no strong evidence of such a relationship in the general population. Furthermore, the results were similar after excluding women whose first breast cancer diagnosis occurred more than 5 years prior to study recruitment, suggesting that any bias is likely to be small. Contralateral breast cancer risks have been shown to be reduced by adjuvant treatment of the first cancer.
24,25
BRCA2 carriers are more likely to develop estrogen receptorpositive cancers, so their lower contralateral breast cancer risk estimates may in part be due to greater use of endocrine therapy. Hormone and chemotherapeutic treatments were not considered, so the present estimates represent risks averaged over different treatments.
There was increasing breast cancer risk for both BRCA1 and BRCA2 carriers with increasing number of relatives who had been diagnosed with breast cancer. Similar patterns were observed for the risk of ovarian cancer but the number of events for women with family history of ovarian cancer was small. The overall breast cancer risk estimates were somewhat higher than those estimated by kin cohort analyses, in which the risks are derived from cohorts of relatives of carriers identified among unselected cases. 3, 21 The present cohort of mutation carriers was primarily identified through clinical genetics centers and included women who, on average, are likely to have stronger family history of cancer compared with mutation carriers identified through population-based sampling of cases. Therefore, a likely explanation for the higher estimated risks in the present study is that cancer risks for mutation carriers are modified by genetic and nongenetic risk factors which aggregate in families, in line with evidence that other genetic factors modify cancer risks for mutation carriers.
18,26-29 This study has several limitations. Data on tumor phenotypes of cancers were not available. Therefore, the results represent average estimates over all phenotypes of breast and ovarian cancer. Although there was variation in the cancer risks for mutation carriers by cancer family history, the study sample was not identified through population screening of unaffected women. Therefore, the overall estimates may not be directly applicable to such women. The present results suggest that cancer risks for women with no family history are likely to be lower than those estimated here. The cancer risk estimates may be subject to some selection bias if the decision to participate in the study or opt for testing was related to factors that are associated with disease risk. It was not possible to contrast the unaffected study participants to all other unaffected family members who had negative test results or who did not opt for a genetic test or for study participation, as those data could not be collected. However, the analysis by family history addresses possible selection bias with respect to family history of cancer and the family history-specific estimates are expected to be unbiased. The number of events in some of the subgroups considered was small and therefore the estimates have wide confidence intervals. Family size was not taken into consideration because data on unaffected family members were not collected systematically. In addition, risk estimates are limited by the lack of information about the use of hormone therapies to prevent either first primary or contralateral breast cancers.
Conclusions
These findings provide information on cancer risk for BRCA1 and BRCA2 mutation carriers using prospective data and demonstrate the potential importance of family history and mutation location in risk assessment. 
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eAppendix. Supplementary Methods and Results
Study Sample
We used data on BRCA1 and BRCA2 mutation carriers recruited through three consortia, the International BRCA1/2 Carrier Cohort Study (IBCCS), the Breast Cancer Family Registry (BCFR) and the Kathleen Cuningham Foundation Consortium for Research Into Familial Breast Cancer (kConFab). We included only female carriers of presumed pathogenic (disease-associated) variants excluding variants of uncertain significance. After excluding dual BRCA1 and BRCA2 mutation carriers, a total of 6036 BRCA1 and 3820 BRCA2 carriers, recruited from 16 countries, were available for analysis (Supplement, eTable 1).
International BRCA1/2 Carrier Cohort Study (IBCCS)
IBCCS was initiated in 1997; its primary aims are to estimate prospectively the risks of breast, ovarian, and other cancers for BRCA1 and BRCA2 carriers and to assess lifestyle and genetic factors that could modify their cancer risks. Details of the design of, and rationale for the study have been described elsewhere 1 . In brief, subjects were eligible to participate in IBCCS if they were carriers of pathogenic mutations in either BRCA1 or BRCA2, >18 years old, capable of giving informed consent and had been counselled as to their mutation carrier status. Data were available from a total of 7666 female mutation carriers (4819 BRCA1, 2847 BRCA2) recruited between 1997 and 2013 from 18 European cancer genetics centres, and from centres in Quebec province, Canada. Of these carriers, 5595 were from large ongoing national studies in the United Kingdom and Eire (EMBRACE), the Netherlands (HEBON), and France (GENEPSO). A standardized questionnaire was administered either by mail, in-person interview at the time of genetic counselling, or through telephone interview, depending on study centre. The questionnaire requested detailed information on known or suspected risk factors for ovarian and breast cancer, including family and reproductive history and surgical interventions. All centres conducted active follow-up for cancer incidence and mortality through follow-up questionnaires. In addition, passive follow-up through linkage with cancer, pathology and death registries has been provided in countries where this is available (cancer/death registries in Denmark, The Netherlands, Sweden and the UK; pathology registries to collect information on preventive surgeries in Denmark and The Netherlands, and through medical record validation of self-reported preventive surgeries).
Breast Cancer Family Registry (BCFR)
BCFR 2 is a family based cohort established in the mid-1990s. It includes six sites, one in Canada, one in Australia and four in the U.S.A.. The BCFR has administered family history and epidemiology questionnaires, and collected biospecimens, and pathology review information, using common protocols, for ~30,000 participants from >9,000 families. Families have been followed up regularly, for example through annual approaches to probands. In particular, there have been three systematic Registrywide follow-ups of all participants that updated epidemiological, family history, treatment and surgery data, the most recent of which was completed in 2014 3 . The Australian, Canadian and Northern Californian sites recruited population-based breast cancer case families using cancer registries. The Australian BCFR recruited women with breast cancer unselected for family history, over-sampling for early age at diagnosis, while the other two population-based sites used a two-stage sampling scheme, over-sampling for early age at diagnosis and/or having a family history or other predictors of a genetic predisposition. The New York, Philadelphia and Utah sites recruited multiple-case families through family cancer clinics and community outreach. Screening for germline BRCA1 and BRCA2 mutations and other known or putative susceptibility variations in other genes has been undertaken as previously described 2, 4, 5 . Data for 1,570 mutation carriers (896 BRCA1 and 686 BRCA2) were
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used in this analysis.
kConFab kConFab has collected epidemiological and family history data from >13,500
participants from >1,600 multiple-case breast cancer families ascertained through 21 family cancer clinics in Australia and New Zealand since 1997 6, 7 . The questionnaires are identical to those used in the BCFR. The eligibility criteria for recruitment of families evolved over time and were intended to maximize the number of living potentially high-risk women, including known mutation carriers, whether affected by breast cancer or not. Female participants recruited prior to November 2008 have been systematically followed from cohort enrolment, by the kConFab Clinical FollowUp study, for cancer outcomes, epidemiological risk factors, and risk management behaviours using a mailed follow-up questionnaire administered every 3 years 8 .
Self-reports of cancers and risk-reducing surgery are confirmed, where possible, by obtaining pathology and surgical reports. Data for 620 mutation carriers (328 BRCA1, 292 BRCA2) were used in this analysis.
The research protocols were approved by the relevant ethics committees and all participants provided written informed consent.
Risk-reducing salpingo-oophorecomy (RRSO) and risk-reducing bilateral mastectomy (RRBM) and censoring process.
Oophorectomy or mastectomy were considered to be risk-reducing, and therefore censoring events in the relevant analyses, if they occurred at least a year prior to ovarian or breast cancer diagnosis. For breast cancers reported within one year of a RRBM, or ovarian cancer diagnoses reported within one year of a RRSO, we considered it likely that the diagnostic process may have been influenced by the surgery, and/or that the dates of surgery or diagnosis may have been inaccurately reported, and did not censor at RRBM or RRSO.
Statistical Analysis
Standardised incidence ratios
Standardised incidence ratios (SIRs) for breast cancer and ovarian cancer, relative to population specific incidences, were estimated using 10-year age intervals. SIRs were calculated separately for BRCA1 and BRCA2 mutation carriers using 10-year age intervals. We used the age and calendar-period specific population disease incidences from Cancer in Five Continents (http://ci5.iarc.fr/Default.aspx) and NORDCAN (http://www-dep.iarc.fr/NORDCAN/english/frame.asp). Because population disease incidences were not available for Hungary, we used the Czech
Republic disease incidences as proxies in this case. SIRs were estimated using Stata version 13. As related individuals were included in these analyses robust standard errors were estimated to account for familial clustering using the formula:
where N is the number of familial clusters, O is the total number of observed events, E is the total expected number of events, O i is the observed number of events in cluster i and E i is the expected number of events in cluster i. The trend in estimated SIRs was tested by a 1df chi-squared score test statistic under assumptions of log-linear models for Poisson variables 9 . Poisson regression was used to test the null hypothesis of no change in the incidences over age-groups, by regressing the agespecific incidence on the ordered age categories.
Variation in risks by family history
To assess whether the breast and ovarian cancer risks differed between family history groups of mutation carriers, we used Cox proportional hazards regression, using clustered observations of family and stratified by country and by birth cohort, as described above. We also used Cox regression to compare risks between those with no family history and those with any family history of breast/ovarian cancer as well as an analysis treating the number of affected relatives as a continuous variable.
In a sensitivity analysis, we restricted the family history classification to cancers among first-degree relatives because some of the participating centres did not record cancers occurring in more distant relatives.
Variation in risks by mutation position and type.
Mutations were grouped into regions by nucleotide position, based on differences in breast and ovarian cancer risks previously reported in retrospective studies [10] [11] [12] 
Results
Breast and ovarian cancer risks by family history
When restricting the family history of cancer to first-degree relatives only, the results were similar for the breast cancer associations (p-trend = 0.001 for BRCA1, 0.046 for BRCA2, Supplement, eTable 9 
